India, March 21 -- The company said the Drug Controller General of India (DCGI) had earlier approved the manufacturing and marketing of the Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications. Zydus stated that, unlike existing treatment options that require patients to purchase multiple single-dose pens during dose titration, it is offering a reusable multi-dose pen device. This innovation allows patients and clinicians to select and administer different dose strengths from a single pen, which the company claims will improve adherence, enhance convenience, and reduce overall treatment costs. The semaglutide injection will be available in a 15 mg/3 ml cartridge and will be manufactured at Zydus...